ArticleScientific reports2025

Propensity score analysis of high-dose rate brachytherapy, immune checkpoint inhibitors, and docetaxel in second-line advanced NSCLC treatment.

Ran Cui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.